Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 5 Identification of mucinous carcinoma

Published byRosaline Nichols Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 5 Identification of mucinous carcinoma"— Presentation transcript:

1 Figure 5 Identification of mucinous carcinoma
Figure 5 | Identification of mucinous carcinoma. a | Sagittal and b | axial T2-weighted MRI scan of a patient with MC, which can be easily recognized owing to the distinctive mucinous high signal intensity on high-resolution MRI images. c,d | H&E-stained tumour (magnification ×1). This Figure emphasizes the need for careful mapping of tumour biopsy samples to preoperative imaging findings, in order to enable personalized medicine, based on initial biopsy. Arrows indicate the presence of mucinous regions of the tumour. Abbreviation: H&E, haematoxylin and eosin. Hugen, N. et al. (2015) Advances in the care of patients with mucinous colorectal cancer Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 5 Identification of mucinous carcinoma"

Similar presentations

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 New functional imaging techniques in lymphoma

Figure 2 New functional imaging techniques in lymphoma
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 3 Intracranial targeting of high-grade gliomas

Figure 3 Intracranial targeting of high-grade gliomas
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 Ex vivo synovial tissue culture viability

Figure 4 Ex vivo synovial tissue culture viability
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Similar presentations

Ads by Google